Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03658785 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunotherapy for the Treatment of Advanced Solid Tumor

StatusUnknown
PhasePhase 1/2
Started2020-04-28
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 13, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Recruiting → Unknown
2024-08-11
Study Status, Eligibility v3
Trial statusRecruiting→Unknown
Eligibility criteria-115 characters
[...] erwise suffer a disadvantage by participating in this study. Patients who have received prior treatment with immunotherapy (eg, anti-PD-1 anti-PD-L1, or anti-CTLA4 antibodies)
2024-01-31
Not Yet Recruiting→Recruiting Study Status, Study Description, Conditions, Arms and Interventions, Outcome Measures, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2023-12-31→2024-12-31
Completion date2024-12-31→2025-12-31
Start dateestimated 2018-12-10→confirmed 2020-04-28
Secondary endpointsdetails revised at 5 of 5 entries
Primary endpoints1 entry, revised
Objective Responce Rate [Time Frame: 24 months after cell infusion]
Study description+17 characters
[...] tment of patients with recurrent, metastatic cervical cancer and liver cancer. TILs specific to personalized neo-antigens will be expende [...]
Study sitesdetails revised at 1 of 1 site
2018-09-05
Study Identification, Study Status, Study Description, Conditions v1
Study descriptionrevised
Adoptive cell transfer therapy that ultilizesutilizes an autologous TIL manufacturing progress is originally deve [...] , metastatic cervical cancer. TILs specific to personalized neoantigensneo-antigens will be expended in vitro and given back to the patients th [...]
2018-09-03
Original filing
Tongji Hospital
197 trials monitored
See 2 trials at risk
The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes (TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and advanced solid tumors.
Trial Details
NCT Number NCT03658785
Lead Sponsor Tongji Hospital
Conditions Recurrence Tumor, Metastatic Cancer, Solid Tumor
Enrollment 40 participants
Start Date 2020-04-28
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-13